Aim: The EGFR inhibitors represent the first-line treatment of non-small-cell lung cancer. However, the emergence of resistance urgently requires the development of new inhibitors targeting drug-resistant mutants. Methodology: A recently released structure of an EGFR kinase domain in complex with an allosteric inhibitor and a mutant protein model derived from it were used to set up a low-cost high-Throughput docking protocol for the fast identification of EGFR allosteric inhibitors. Conclusion: The virtual screening of commercially available compounds led to the identification of interesting new hit compounds. The most promising hit was confirmed to be a new allosteric inhibitor of wild-Type and T790M/L858R double mutant EGFR which was able to inhibit the growth of non-small-cell lung cancer cell lines.
Identification of small-molecule EGFR allosteric inhibitors by high-Throughput docking / Caporuscio, Fabiana; Tinivella, Annachiara; Restelli, Valentina; Semrau, Marta S; Pinzi, Luca; Storici, Paola; Broggini, Massimo; Rastelli, Giulio. - In: FUTURE MEDICINAL CHEMISTRY. - ISSN 1756-8919. - 10:13(2018), pp. 1545-1553. [10.4155/fmc-2018-0063]
Identification of small-molecule EGFR allosteric inhibitors by high-Throughput docking
Caporuscio, Fabiana;Tinivella, Annachiara;Semrau, Marta S;Pinzi, Luca;Rastelli, Giulio
2018
Abstract
Aim: The EGFR inhibitors represent the first-line treatment of non-small-cell lung cancer. However, the emergence of resistance urgently requires the development of new inhibitors targeting drug-resistant mutants. Methodology: A recently released structure of an EGFR kinase domain in complex with an allosteric inhibitor and a mutant protein model derived from it were used to set up a low-cost high-Throughput docking protocol for the fast identification of EGFR allosteric inhibitors. Conclusion: The virtual screening of commercially available compounds led to the identification of interesting new hit compounds. The most promising hit was confirmed to be a new allosteric inhibitor of wild-Type and T790M/L858R double mutant EGFR which was able to inhibit the growth of non-small-cell lung cancer cell lines.File | Dimensione | Formato | |
---|---|---|---|
caporuscio2018.pdf
Accesso riservato
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
2.79 MB
Formato
Adobe PDF
|
2.79 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris